Coronavirus delays Biogen's Spinraza for some patients

U.S. drugmaker Biogen Inc said on Wednesday that some patients on its drug Spinraza - which treats a rare disorder called spinal muscular atrophy (SMA) - are having their treatments postponed to prioritize COVID-19 patients.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.